Novartis announces Cosentyx met primary endpoint in Phase III REPLENISH trial

Novartis (NVS) today announced that Cosentyx met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial. Cosentyx demonstrated statistically significant and clinically meaningful sustained remission vs placebo at Week 52 in adults with polymyalgia rheumatica. Data will be presented at an upcoming medical congress and submitted to health authorities in the first half of 2026. A key secondary endpoint of the REPLENISH trial was adjusted annual cumulative steroid dose through Week 52. Other secondary measures included complete sustained remission at Week 52, and time until patients needed additional treatment.